StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTIQ) stock

KPTIQPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
Share price
Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Karyopharm Therapeutics Inc. grew revenue 6.8% to $146.62M over the twelve months to Jun 30, 2026. Free cash flow was -$75.37M.

Revenue
$146.62M
+6.8% vs. a year earlier
Operating income
-$82.35M
TTM Q2 2026
Free cash flow
-$75.37M
FY2025
EPS, diluted
-$17.93
FY2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
–
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$146.62M
Net income
-$224.74M
EPS, diluted
-$17.93
Free cash flow
-$75.37M
Book value per share
-$11409.50
Diluted shares
0M

Valuation needs the share price. It fills in once daily prices are connected.

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$146.62M+6.8% YoY

Operating income

-$82.35M

Net income

-$224.74M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Karyopharm Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K.
    Update
  2. Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
    Update
  3. Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
    Update
  4. Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
    Results
  5. Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
    Results
  6. Karyopharm’s Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
    Update
All press releases and earnings

About Karyopharm Therapeutics

Pharmaceutical Preparations

Karyopharm Therapeutics Inc. is a pharmaceutical company that focuses on the discovery, development, and commercialization of treatments such as Xpovio. Operating within the healthcare sector, the business develops product candidates and enters into commercial collaborations and licensing agreements with partner firms, including Menarini and Antengene Therapeutics. Through these arrangements, the company provides products and licenses its pharmaceutical assets to partners and customers across the industry.

Company profile, executives and history

Karyopharm Therapeutics stock: common questions

What is KPTIQ's P/E ratio?

Karyopharm Therapeutics lost money over fiscal 2025 (diluted EPS -$17.93), so it has no meaningful P/E ratio.

How much revenue does Karyopharm Therapeutics make?

Karyopharm Therapeutics reported revenue of $146.62M for the twelve months to Jun 30, 2026, up 6.8% from a year earlier.

Does Karyopharm Therapeutics pay a dividend?

No. Karyopharm Therapeutics has not paid a cash dividend over the last twelve months.

Who are Karyopharm Therapeutics's competitors?

Companies most similar to Karyopharm Therapeutics by business, industry and size include LGND, AMRN, IDYA, TNGX, AKBA.

See a number that looks wrong?